Natco Pharma rallies 7% as firm seeks nod for Covid medicine Molnupiravir

Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of Covid-19 replication

Investors rushed to pick shares of Natco Pharma on the BSE on Monday as the firm sought Central Drugs Standard Control Organization's (CDSCO's) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients. At 11:30 am, shares of the pharmaceutical firm were ruling 5 per cent higher on the BSE, at Rs 923 apiece, as against a 1.4 per cent rise in the benchmark S&P BSE Sensex. In the intra-day deals, the shares surged 7.5 per cent to Rs 944 per share on the BSE. 

"Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity,